PPT-New Advances for NAFLD/NASH

New Advances for NAFLDNASH NAFLD A Spectrum of Disease Who Is at Risk for NAFLD and NASH Prevalence of NAFLD in Europe Prevalence of NAFLD and NASH Predicted to Increase in Europe What Is the Burden of NAFLD in Europe. NAFLD. Hepatic . Manifestation of Metabolic Syndrome. a. NAFLD (cont). Hepatic . Manifestation of Metabolic Syndrome. a. NAFLD/NASH Closely Associated With Visceral Obesity, Insulin Resistance. AASLD. Masi. . Khaja. , M.D. Objectives . Epidemiology. Natural History. Clinical Presentation. Pathogenesis. Approach to Diagnosis. Treatment. What is NAFLD?. Nonalcoholic Fatty Liver Disease. [NAFLD]. STEATOSIS. Disease. . s_khalilzadeh. A Novel. Cardiometabolic Risk Factor for Type 2 Diabetes. NAFLD and T2DM. NAFLD is closely associated with features of the metabolic. syndrome and is regarded as the hepatic manifestation. Fatty Liver Disease. Anna Christina Dela Cruz, MD. Division of Digestive Diseases and Nutrition . Conflict of Interest. None. Upon completion of this activity, participants will be able to: . Select appropriate diagnostic testing for the evaluation of gastrointestinal comorbidities in patients with diabetes.. adults. Dr.mousavi. -Abadan-. Khordad. 1397 . DEFINITIONS — Patients with nonalcoholic fatty liver disease (NAFLD) . have hepatic . steatosis. , . with or without . inflammation and fibrosis. . In addition, . Moderator. Kris V. Kowdley, MD . Director . Liver Institute Northwest . Clinical Professor. Elson S. Floyd College of Medicine. Washington State University. Seattle, Washington . Overview of Discussion. Hepatologist. East & North Hertfordshire NHS Trust. Royal Free London NHS Foundation Trust. ELF Research Group. University College London. Liver disease. Scale of the problem. Liver disease is the 5. Sezione di Gastroenterologia e Epatologia, . Di.Bi.M.I.S.,University of Palermo, Italy. salvatore.petta@unipa.it; petsa@inwind.it. About these slides. These slides provide highlights of new data presented at the EASL NAFLD Summit 2019. Please feel free to use, adapt and share these slides for your own personal use; however, please acknowledge EASL as the source. William Alazawi MA(. Cantab. ) PhD MRCP. Senior Lecturer and Consultant in . Hepatology. Queen Mary, University of London. Does Liver Disease Matter?. Mortality in England & Wales. Liver-related mortality in under 65s. Josep M . Llovet,. MD, PhD. Professor of Medicine. Director, Liver Cancer Program. ISM at Mount Sinai, NYC. Professor of Research-ICREA. Head, Translational research in hepatic oncology. Liver Unit. Hospital . Non-Alcoholic Fatty Liver Disease (NAFLD)/ . Non-Alcoholic Steatohepatitis (NASH). Dr.. . Ranjitsinh. Devkar. Asst. Professor Department of Zoology, . The . M.S.University. of Baroda, Vadodara, India. Rohit . Pai. MD, FRCPC. Gastroenterology and Hepatology. Island Health and Pacific Digestive Health. Clinical Assistant Professor, UBC. Liver Care Clinic, Royal . Jubillee. Hospital. Disclosures. Research: Intercept. in Hepatocellular Carcinoma: . Real-World Experience and Treatment Sequencing with NASH/NAFLD Risk Factors. Sammy Saab, . MD, MPH, AGAF, FACG, FAASLD. Medical Director, Pfleger Liver Institute. Medical Director, Adult Liver Transplant Program.